daunorubicin has been researched along with sirolimus in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Arceci, RJ; Bierer, BE; Stieglitz, K | 1 |
| Christians, U; Demmer, A; Hoof, T; Tümmler, B | 1 |
| Do, DV; Han, HC; Khoo, YT; Lim, IJ; Mukhopadhyay, A; Ong, CT; Phan, TT; Tan, EK | 1 |
| Gong, YP; He, GC; Lin, J | 1 |
| Gong, Y; Guo, Y; He, G; Lin, J; Ma, H; Shan, Q; Shuai, X; Yang, X; Zhou, R | 1 |
| Béné, MC; Bories, P; Bouscary, D; Cahn, JY; Chapuis, N; Chevallier, P; Delepine, R; Demur, C; Dreyfus, F; Ifrah, N; Lacombe, C; Lamy, T; Leguay, T; Mayeux, P; Merlat, A; Park, S; Prebet, T; Recher, C; Saint Marcoux, F; Tamburini, J; Vey, N; Witz, F | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
1 review(s) available for daunorubicin and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for daunorubicin and sirolimus
| Article | Year |
|---|---|
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Everolimus; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2013 |
8 other study(ies) available for daunorubicin and sirolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Binding, Competitive; Daunorubicin; Drug Resistance; Drug Synergism; Humans; Iodine Radioisotopes; Membrane Glycoproteins; Phenotype; Polyenes; Prazosin; Sirolimus; Tacrolimus; Tumor Cells, Cultured | 1992 |
Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin.
Topics: Affinity Labels; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cell Division; Cell Membrane; CHO Cells; Cricetinae; Cricetulus; Cyclosporine; Daunorubicin; Drug Resistance; Immunosuppressive Agents; Membrane Glycoproteins; Polyenes; Sirolimus; Succinimides; Tacrolimus; Vinca Alkaloids | 1993 |
Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Coculture Techniques; Culture Media, Conditioned; Daunorubicin; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Fibroblasts; Humans; Immunohistochemistry; Keloid; Keratinocytes; Mesoderm; Mitoxantrone; Neovascularization, Pathologic; Sirolimus; Statistics, Nonparametric; Up-Regulation; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
[Effect of daunorubicin and rapamycin combination on the proliferation of acute leukemia cells].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Daunorubicin; Female; Humans; Leukemia; Male; Middle Aged; Sirolimus; Young Adult | 2011 |
Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.
Topics: Adult; Autophagy; Cell Division; Cell Line, Tumor; Daunorubicin; Drug Synergism; Humans; K562 Cells; Neoplasm Proteins; Phagosomes; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Processing, Post-Translational; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2012 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |